Why Orexo is abandoning a digital therapeutic for depression

Swedish pharmaceutical company Orexo will no longer pursue an app for treating depression after many years of struggling to sell it.

Orexo announced this week that it will no longer license the product, called Deprexis, from German manufacturer GAIA. The two companies have worked together on Deprexis in the United States since 2020, and have deals for two other apps, including Modia, an app that provides psychosocial support to people being treated for opioid addiction.

For a company that has had trouble with getting reimbursed for its digital therapeutics in the U.S., the timing of Orexo’s decision to pull the plug on Deprexis is surprising: just weeks after Medicare created a pathway for some digital mental health treatments to get paid.

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Popular nasal decongestant doesn’t actually relieve congestion, FDA experts say

WASHINGTON — The leading decongestant used by millions of Americans looking for relief from a stuffy nose is no better than a dummy pill, according

September 12, 2023

US trade commission explores impact of patent rules on COVID diagnostics

Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: The U.S. International Trade Commission

October 23, 2023

Mainz Biomed seeks FDA’s Breakthrough Devices Designation for advanced colorectal cancer test

Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced that it has submitted its application to the U.S.

July 13, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.